Development asset linked to Anhui Provincial Hospital in public FDA and regional records.
pharma · Hepatocellular Carcinoma · Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
Anhui Provincial Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Anhui Provincial Hospital pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Anhui Provincial Hospital drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Anhui Provincial Hospital in public FDA and regional records.
-
Development asset linked to Anhui Provincial Hospital in public FDA and regional records. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 binding agent
-
Development asset linked to Anhui Provincial Hospital in public FDA and regional records.
-
Development asset linked to Anhui Provincial Hospital in public FDA and regional records.